Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer
2018
Background
Obesity and type II diabetes are linked to increased breast cancer risk in postmenopausal women. Patients treated with the antidiabetic drug metformin for diabetes or metabolic syndrome have reduced breast cancer risk, a greater pathologic complete response to neoadjuvant therapy, and improved breast cancer survival. We hypothesized that metformin may be especially effective when targeted to the menopausal transition, as this is a lifecycle window when weight gain and metabolic syndrome increase, and is also when the risk for obesity-related breast cancer increases.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
63
References
28
Citations
NaN
KQI